JP5199885B2 - プロテインキナーゼｂ（ｐｋｂ）阻害剤としてのチアゾール化合物 - Google Patents

プロテインキナーゼｂ（ｐｋｂ）阻害剤としてのチアゾール化合物 Download PDF

Info

Publication number
JP5199885B2
JP5199885B2 JP2008551297A JP2008551297A JP5199885B2 JP 5199885 B2 JP5199885 B2 JP 5199885B2 JP 2008551297 A JP2008551297 A JP 2008551297A JP 2008551297 A JP2008551297 A JP 2008551297A JP 5199885 B2 JP5199885 B2 JP 5199885B2
Authority
JP
Japan
Prior art keywords
thiazol
amino
phenyl
trifluoromethyl
amine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2008551297A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009525960A5 (US08084479-20111227-C00036.png
JP2009525960A (ja
Inventor
チヨン，チンピン
アレン，ジヨン・ジー
ブルボー，マシユー・ピー
ドミンゲス，セリア
フオツシユ，クリストフアー・エイチ
ハン，ニアンホー
ホン，フアン−ツアオ
ホワン，シン
リー，マシユー・アール
リ，アイウエン
リユウ，チンイアン
ライダー，ジエームズ・テイー
タデツセ，セイフ
タスカー，アンドリユー・エス
ビスワナダン，ベラーカド・エヌ
ワン，シヤンホン
ワイラー、クルト・イー
ウオールヒーター，ジヨージ・イー
ヤオ，クオミン
ユアン，チエスター・チエンクワン
Original Assignee
アムジエン・インコーポレーテツド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アムジエン・インコーポレーテツド filed Critical アムジエン・インコーポレーテツド
Publication of JP2009525960A publication Critical patent/JP2009525960A/ja
Publication of JP2009525960A5 publication Critical patent/JP2009525960A5/ja
Application granted granted Critical
Publication of JP5199885B2 publication Critical patent/JP5199885B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
JP2008551297A 2006-01-18 2007-01-11 プロテインキナーゼｂ（ｐｋｂ）阻害剤としてのチアゾール化合物 Expired - Fee Related JP5199885B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US75954606P 2006-01-18 2006-01-18
US60/759,546 2006-01-18
PCT/US2007/000871 WO2007084391A2 (en) 2006-01-18 2007-01-11 Thiazole compounds as protein kinase b ( pkb) inhibitors

Publications (3)

Publication Number Publication Date
JP2009525960A JP2009525960A (ja) 2009-07-16
JP2009525960A5 JP2009525960A5 (US08084479-20111227-C00036.png) 2010-01-21
JP5199885B2 true JP5199885B2 (ja) 2013-05-15

Family

ID=38180602

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008551297A Expired - Fee Related JP5199885B2 (ja) 2006-01-18 2007-01-11 プロテインキナーゼｂ（ｐｋｂ）阻害剤としてのチアゾール化合物

Country Status (21)

Country Link
US (2) US7514566B2 (US08084479-20111227-C00036.png)
EP (1) EP1981884B1 (US08084479-20111227-C00036.png)
JP (1) JP5199885B2 (US08084479-20111227-C00036.png)
KR (1) KR20080091369A (US08084479-20111227-C00036.png)
CN (1) CN101421265A (US08084479-20111227-C00036.png)
AR (1) AR059064A1 (US08084479-20111227-C00036.png)
AU (1) AU2007207743B2 (US08084479-20111227-C00036.png)
BR (1) BRPI0706621A2 (US08084479-20111227-C00036.png)
CA (1) CA2636077C (US08084479-20111227-C00036.png)
CR (1) CR10211A (US08084479-20111227-C00036.png)
EA (1) EA200801716A1 (US08084479-20111227-C00036.png)
ES (1) ES2389062T3 (US08084479-20111227-C00036.png)
IL (1) IL192751A0 (US08084479-20111227-C00036.png)
MY (1) MY149143A (US08084479-20111227-C00036.png)
NO (1) NO20083572L (US08084479-20111227-C00036.png)
PE (1) PE20071114A1 (US08084479-20111227-C00036.png)
TW (1) TW200738657A (US08084479-20111227-C00036.png)
UA (1) UA91895C2 (US08084479-20111227-C00036.png)
UY (1) UY30098A1 (US08084479-20111227-C00036.png)
WO (1) WO2007084391A2 (US08084479-20111227-C00036.png)
ZA (1) ZA200806386B (US08084479-20111227-C00036.png)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007004551A (es) 2004-10-18 2007-05-23 Amgen Inc Compuestos tiadiazol y metodos de uso.
ES2389062T3 (es) * 2006-01-18 2012-10-22 Amgen, Inc Compuestos de tiazol como inhibidores de proteína cinasa B (PKB)
RU2009134059A (ru) * 2007-02-13 2011-03-20 Шеринг Корпорейшн (US) Функционально селективные агонисты альфа2с адренорецептора
WO2009011871A2 (en) 2007-07-17 2009-01-22 Amgen Inc. Thiadiazole modulators of pkb
EP2173728A2 (en) * 2007-07-17 2010-04-14 Amgen Inc. Heterocyclic modulators of pkb
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
EP2303017A4 (en) * 2008-06-26 2011-06-15 Glaxosmithkline Llc HAMMER OF ACT ACTIVITY
BRPI0917394A2 (pt) * 2008-08-18 2019-09-24 Univ Yale moduladores de mif
US9540322B2 (en) 2008-08-18 2017-01-10 Yale University MIF modulators
US9643922B2 (en) 2008-08-18 2017-05-09 Yale University MIF modulators
PT2356109T (pt) * 2008-10-10 2017-03-10 Vm Discovery Inc Composições e métodos para o tratamento distúrbios de utilização de álcool, dor e outras doenças
EP2373163B1 (en) * 2008-12-19 2015-06-10 Genentech, Inc. Heterocyclic compounds and methods of use
US20110263647A1 (en) * 2009-01-15 2011-10-27 Amgen Inc. Fluoroisoquinoline substituted thiazole compounds and methods of use
EP2440556A1 (en) * 2009-06-10 2012-04-18 Vertex Pharmaceuticals Incorporated Inhibitors of phosphatidylinositol 3-kinase
FI2445502T4 (fi) 2009-06-25 2023-01-13 Heterosyklisiä yhdisteitä neurologisten ja psykologisten häiriöiden hoitamiseksi
BR112012008271A2 (pt) * 2009-10-08 2015-09-22 Glaxosmithkline Llc combinação
EP2485594B1 (en) * 2009-10-08 2015-01-07 GlaxoSmithKline LLC Combination
BR112012008519A2 (pt) * 2009-10-12 2016-04-05 Glaxosmithkline Llc combinação
WO2011049625A1 (en) 2009-10-20 2011-04-28 Mansour Samadpour Method for aflatoxin screening of products
MX352661B (es) 2009-11-05 2017-12-04 Rhizen Pharmaceuticals S A Star Moduladores novedosos de benzopiran cinasa.
JP5747352B2 (ja) * 2010-03-15 2015-07-15 国立大学法人広島大学 チエノピリジン誘導体を用いた有機半導体デバイス
JP5578705B2 (ja) * 2010-03-29 2014-08-27 公益財団法人相模中央化学研究所 （アリール）ジフルオロ酢酸エステル誘導体及びその製造方法
WO2011130478A1 (en) * 2010-04-16 2011-10-20 Abbott Laboratories Phthalazin-(2h)-one inhibitors of kinases
WO2011130921A1 (en) * 2010-04-23 2011-10-27 Merck Sharp & Dohme Corp. Inhibitors of akt activity
EP2579872A4 (en) * 2010-04-23 2013-11-13 Merck Sharp & Dohme HAMMER OF ACT ACTIVITY
JO2998B1 (ar) 2010-06-04 2016-09-05 Amgen Inc مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان
PL2705029T4 (pl) 2011-05-04 2019-04-30 Rhizen Pharmaceuticals S.A. Nowe związki jako modulatory kinaz białkowych
EP2760845B1 (en) 2011-09-27 2016-11-16 Amgen Inc. Heterocyclic compounds as mdm2 inhibitors for the treatment of cancer
CN103304468A (zh) * 2012-03-13 2013-09-18 华东师范大学 一种氧化吲哚的一锅法串联合成方法
JPWO2013146754A1 (ja) * 2012-03-27 2015-12-14 塩野義製薬株式会社 Ｔｒｐｖ４阻害活性を有する芳香族複素５員環誘導体
WO2013173382A1 (en) 2012-05-15 2013-11-21 Amgen Inc. Benzothiophene sulfonamides and other compounds that interact with glucokinase regulatory protein
PL2870157T3 (pl) 2012-07-04 2018-01-31 Rhizen Pharmaceuticals S A Selektywne inhibitory pi3k delta
AU2014219075C1 (en) 2013-02-19 2018-09-06 Amgen Inc. Cis-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer
SG11201507346PA (en) * 2013-03-13 2015-10-29 Boston Biomedical Inc 3-(aryl or heteroaryl) methyleneindolin-2-one derivatives as inhibitors of cancer stem cell pathway kinases for the treatment of cancer
JP6377123B2 (ja) 2013-03-14 2018-08-22 アムジエン・インコーポレーテツド 癌の治療のためのｍｄｍ２阻害剤としてのヘテロアリール酸モルホリノン化合物
JOP20200296A1 (ar) 2013-06-10 2017-06-16 Amgen Inc عمليات صنع وأشكال بلورية من mdm2 مثبط
BR112016010564A2 (pt) 2013-11-11 2017-10-10 Amgen Inc terapia de combinação incluindo um inibidor de mdm2 e um ou mais agentes farmaceuticamente ativos para tratamento de cânceres
MX371167B (es) * 2015-03-02 2020-01-21 Rigel Pharmaceuticals Inc Inhibidores de inhibidores del factor beta de crecimiento de transformacion (tgf-beta).
US20190060286A1 (en) 2016-02-29 2019-02-28 University Of Florida Research Foundation, Incorpo Chemotherapeutic Methods
CA3015893C (en) * 2016-03-10 2021-11-09 Astrazeneca Ab Novel inhibitors of phosphatidylinositol 3-kinase gamma
CR20190424A (es) 2017-03-30 2019-11-04 Hoffmann La Roche Isoquinolinas como inhibidores de hpk1
JOP20190272A1 (ar) 2017-05-22 2019-11-21 Amgen Inc مثبطات kras g12c وطرق لاستخدامها
PT3691620T (pt) 2017-10-05 2022-10-06 Fulcrum Therapeutics Inc Os inibidores da quinase p38 reduzem a expressão de dux4 e genes a jusante para o tratamento de fshd
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
AU2019230014A1 (en) 2018-03-05 2020-09-17 Alkermes Pharma Ireland Limited Aripiprazole dosing strategy
EP3788038B1 (en) 2018-05-04 2023-10-11 Amgen Inc. Kras g12c inhibitors and methods of using the same
US11612606B2 (en) 2018-10-03 2023-03-28 Genentech, Inc. 8-aminoisoquinoline compounds and uses thereof
JP7377679B2 (ja) 2018-11-19 2023-11-10 アムジエン・インコーポレーテツド がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法
EP3738593A1 (en) 2019-05-14 2020-11-18 Amgen, Inc Dosing of kras inhibitor for treatment of cancers
WO2020236947A1 (en) 2019-05-21 2020-11-26 Amgen Inc. Solid state forms
MX2022001302A (es) * 2019-08-02 2022-03-02 Amgen Inc Inhibidores de kif18a.
US20240139193A1 (en) 2019-10-15 2024-05-02 Amgen Inc. Combination therapy of kras inhibitor and shp2 inhibitor for treatment of cancers
US20230028414A1 (en) 2019-12-16 2023-01-26 Amgen Inc. Dosing regimen of kras g12c inhibitor
CN111603466B (zh) * 2020-06-29 2022-07-22 江南大学 一种乙酮类化合物在制备治疗肿瘤药物中的应用
CN114014787B (zh) * 2022-01-10 2022-03-22 苏州开元民生科技股份有限公司 一种制备(2s,3r)-对甲砜基苯丝氨酸乙酯的不对称合成方法
CN116813608B (zh) * 2023-06-08 2024-03-22 英矽智能科技(上海)有限公司 噻唑类化合物及其应用

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3591600A (en) 1969-07-07 1971-07-06 Stauffer Chemical Co 2-aminothiazole phosphates and phosphonates
GB1435139A (en) 1972-08-17 1976-05-12 Sumitomo Chemical Co Thiazole derivatives
JPS5239827B2 (US08084479-20111227-C00036.png) 1973-11-08 1977-10-07
US4086239A (en) 1977-07-01 1978-04-25 Stauffer Chemical Company Thiazole bis-phosphates and phosphonates, intermediates, and insecticidal compositions and methods
DK150068C (da) 1978-06-02 1987-06-29 Pfizer Analogifremgangsmaade til fremstilling af aminothiazoler
US4297365A (en) 1978-08-04 1981-10-27 Ciba-Geigy Corporation Benzimidazoles and pharmaceutical preparations containing such compounds
US4451471A (en) 1981-03-18 1984-05-29 Ciba-Geigy Corporation Certain 2,4,5-tri-substituted thiazoles, pharmaceutical compositions containing same and methods of using same
FR2511375A1 (fr) 1981-08-17 1983-02-18 Rhone Poulenc Sante Nouveaux derives de la cephalosporine, leur preparation et les medicaments qui les contiennent
DE3630732A1 (de) 1986-09-10 1988-03-17 Bayer Ag 2-cyano-2-alkoximino-acetamide
US5232921A (en) 1987-03-12 1993-08-03 Sanofi Thiazole derivatives active on the cholinergic system, process for obtention and pharmaceutical compositions
JPH0753666B2 (ja) 1987-09-14 1995-06-07 久光製薬株式会社 置換ジフェニルチアゾール誘導体からなる抗炎症剤
FR2636628B1 (fr) 1988-08-25 1990-12-28 Sanofi Sa Derives du thiadiazole-1,3,4, leur procede d'obtention et compositions pharmaceutiques en contenant
US5302608A (en) 1988-11-18 1994-04-12 Takeda Chemical Industries, Ltd. Age formation inhibitors
US5145860A (en) 1989-01-05 1992-09-08 Fujisawa Pharmaceutical Co., Ltd. Thiazole compounds and pharmaceutical composition comprising the same
US5550138A (en) 1992-03-25 1996-08-27 Takeda Chemical Industries, Ltd. Condensed thiadiazole derivative, method of its production, and use thereof
WO1996016650A1 (fr) 1994-11-29 1996-06-06 Hisamitsu Pharmaceutical Co., Inc. Antibacterien et bactericide comprenant un derive de 2-aminothiazole et sels de ce derive
FR2735777B1 (fr) * 1995-06-21 1997-09-12 Sanofi Sa Derives de 4-phenylaminothiazole, leur procede de preparation et les compositions pharmaceutiques les contenant
US6407124B1 (en) * 1998-06-18 2002-06-18 Bristol-Myers Squibb Company Carbon substituted aminothiazole inhibitors of cyclin dependent kinases
CA2332325A1 (en) 1998-06-18 1999-12-23 Bristol-Myers Squibb Company Carbon substituted aminothiazole inhibitors of cyclin dependent kinases
GB9823873D0 (en) 1998-10-30 1998-12-30 Pharmacia & Upjohn Spa 2-ureido-thiazole derivatives,process for their preparation,and their use as antitumour agents
AU3487500A (en) 1999-02-08 2000-08-25 Lion Bioscience Ag Thiazole derivatives and combinatorial libraries thereof
AUPP873799A0 (en) 1999-02-17 1999-03-11 Fujisawa Pharmaceutical Co., Ltd. Pyridine compounds
UA71971C2 (en) 1999-06-04 2005-01-17 Agoron Pharmaceuticals Inc Diaminothiazoles, composition based thereon, a method for modulation of protein kinases activity, a method for the treatment of diseases mediated by protein kinases
CA2381215A1 (en) 1999-08-06 2001-02-15 Takeda Chemical Industries, Ltd. P38map kinase inhibitors
JP2001114690A (ja) * 1999-08-06 2001-04-24 Takeda Chem Ind Ltd ｐ３８ＭＡＰキナーゼ阻害剤
AU2001244618A1 (en) 2000-03-30 2001-10-15 Takeda Chemical Industries Ltd. Substituted 1,3-thiazole compounds, their production and use
WO2001074793A2 (en) * 2000-04-03 2001-10-11 3-Dimensional Pharmaceuticals, Inc. Substituted thiazoles and the use thereof as inhibitors of plasminogen activator inhibitor-1
US7074934B2 (en) 2000-06-13 2006-07-11 Tularik Limited Serine protease inhibitors
GT200100147A (es) 2000-07-31 2002-06-25 Derivados de imidazol
JP4689801B2 (ja) 2000-08-09 2011-05-25 ケミプロ化成株式会社 アミノチアゾール誘導体の製造方法
JP2002053566A (ja) 2000-08-11 2002-02-19 Japan Tobacco Inc チアゾール化合物及びその医薬用途
GB0114185D0 (en) 2001-06-12 2001-08-01 Protherics Molecular Design Lt Compounds
US20040097555A1 (en) 2000-12-26 2004-05-20 Shinegori Ohkawa Concomitant drugs
AR032653A1 (es) 2001-02-09 2003-11-19 Telik Inc Inhibidores heterociclicos del trasportador de glicina 2 composiciones farmaceuticas, uso y metodos.
EP1256578B1 (en) * 2001-05-11 2006-01-11 Pfizer Products Inc. Thiazole derivatives and their use as cdk inhibitors
US20050080113A1 (en) 2001-06-11 2005-04-14 Shigenori Ohkawa Medicinal compositions
AR039059A1 (es) 2001-08-06 2005-02-09 Sanofi Aventis Compuesto derivado de acilaminotiazol, su utilizacion, procedimientos para prepararlo, composicion farmaceutica que lo comprende, y compuestos intermediarios
CA2460909A1 (en) * 2001-09-28 2003-04-10 Cyclacel Limited N-(4-(4-methylthiazol-5-yl) pyrimidin-2-yl) -n-phenylamines as antiproliferative compounds
GB0123589D0 (en) 2001-10-01 2001-11-21 Syngenta Participations Ag Organic compounds
EP1441732A2 (en) 2001-11-08 2004-08-04 Fujisawa Pharmaceutical Co., Ltd. Thiazole derivative and pharmaceutical use thereof
CA2472763A1 (en) 2002-02-13 2003-08-21 Pharmagene Laboratories Limited 5-ht2b receptor antagonists
PE20030968A1 (es) 2002-02-28 2004-01-12 Novartis Ag Derivados de 5-feniltiazol como inhibidores de cinasas
KR100611854B1 (ko) * 2002-02-28 2006-08-11 에프. 호프만-라 로슈 아게 신경 펩타이드 ｙ(ｎｐｙ) 수용체 길항제로서의 티아졸유도체
US20040053948A1 (en) 2002-05-10 2004-03-18 Cytokinetics, Inc. Compounds, compositions and methods
FR2842523A1 (fr) 2002-07-17 2004-01-23 Sanofi Synthelabo Derives d'acylaminothiazole, leur preparation et leur application en therapeutique
KR20050070046A (ko) 2002-10-09 2005-07-05 화이자 프로덕츠 인크. 퇴행성신경 장애 치료를 위한 티아졸 화합물
CA2504320A1 (en) * 2002-10-30 2004-05-21 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of rock and other protein kinases
GB0226583D0 (en) 2002-11-14 2002-12-18 Cyclacel Ltd Compounds
AR042052A1 (es) 2002-11-15 2005-06-08 Vertex Pharma Diaminotriazoles utiles como inhibidores de proteinquinasas
US20050004186A1 (en) 2002-12-20 2005-01-06 Pfizer Inc MEK inhibiting compounds
FR2850380B1 (fr) 2003-01-23 2006-07-07 Sanofi Synthelabo Derives d'acylaminothiazole, leur preparation et leur utilisation en therapeutique
JP2006182648A (ja) 2003-04-08 2006-07-13 Dai Ichi Seiyaku Co Ltd ７員複素環誘導体
AR044519A1 (es) * 2003-05-02 2005-09-14 Novartis Ag Derivados de piridin-tiazol amina y de pirimidin-tiazol amina
JP2007512230A (ja) * 2003-08-20 2007-05-17 バーテックス　ファーマシューティカルズ　インコーポレイテッド プロテインキナーゼ阻害剤として有用な（４−アミノ−１，２，５−オキサジアゾール−４−イル）−ヘテロ芳香族化合物
RU2006111093A (ru) 2003-09-06 2007-10-27 Вертекс Фармасьютикалз Инкорпорейтед (Us) Модуляторы атр-связывающих кассетных транспортеров
GB0327380D0 (en) 2003-11-25 2003-12-31 Cyclacel Ltd Method
GB0329275D0 (en) 2003-12-18 2004-01-21 Merck Sharp & Dohme Therapeutic treatment
DE602005001931T2 (de) 2004-01-12 2008-04-24 Applied Research Systems Ars Holding N.V. Thiazolderivate und deren verwendung
DK1709018T3 (da) 2004-01-16 2011-11-14 Sanofi Sa Acylaminothiazolderivater og anvendelse deraf som beta-amyloid-hæmmere
NZ548531A (en) 2004-01-16 2010-01-29 Sanofi Aventis Acylaminothiazole derivatives, preparation method thereof and use of same in therapeutics
JP2007526324A (ja) * 2004-03-02 2007-09-13 スミスクライン・ビーチャム・コーポレイション Ａｋｔ活性のある阻害剤
KR100814599B1 (ko) 2004-03-23 2008-03-17 화이자 프로덕츠 인크. 신경퇴행성 장애 치료용 이미다졸 화합물
CA2561977A1 (en) 2004-03-30 2005-10-13 Chiron Corporation Substituted thiophene derivatives as anti-cancer agents
EP1740609A2 (en) * 2004-04-27 2007-01-10 Research Development Foundation Antagonism of tgf-beta superfamily receptor signaling
WO2005113579A1 (en) 2004-05-21 2005-12-01 Mpex Pharmaceuticals, Inc. Bacterial efflux pump inhibitors and methods of treating bacterial infections
GB0411791D0 (en) 2004-05-26 2004-06-30 Cyclacel Ltd Compounds
MX2007001727A (es) 2004-08-13 2007-04-20 Genentech Inc Compuestos a base de 2-amido-tiazol que exhiben actividad inhibidora de enzima que utiliza atp y composiciones y usos de los mismos.
WO2006038734A1 (en) 2004-10-08 2006-04-13 Astellas Pharma Inc. Pyridazinone derivatives cytokines inhibitors
MX2007004551A (es) 2004-10-18 2007-05-23 Amgen Inc Compuestos tiadiazol y metodos de uso.
SE0402735D0 (sv) 2004-11-09 2004-11-09 Astrazeneca Ab Novel compounds
US20060178388A1 (en) 2005-02-04 2006-08-10 Wrobleski Stephen T Phenyl-substituted pyrimidine compounds useful as kinase inhibitors
WO2006093247A1 (ja) 2005-02-28 2006-09-08 Japan Tobacco Inc. Ｓｙｋ阻害活性を有する新規なアミノピリジン化合物
EP2314574A1 (en) 2005-06-17 2011-04-27 Apogee Biothechnology Corporation Sphingosine kinase inhibitors
WO2007008541A2 (en) 2005-07-08 2007-01-18 Kalypsys, Inc. Cellular cholesterol absorption modifiers
DE102005048072A1 (de) 2005-09-24 2007-04-05 Bayer Cropscience Ag Thiazole als Fungizide
JP5064237B2 (ja) 2005-12-09 2012-10-31 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 リンコマイシン誘導体およびこれを有効成分とする抗菌剤
KR20080080170A (ko) 2005-12-12 2008-09-02 제네랩스 테크놀로지스, 인코포레이티드 Ｎ-(5원 헤테로방향족 고리)-아미도 항바이러스 화합물
ES2389062T3 (es) * 2006-01-18 2012-10-22 Amgen, Inc Compuestos de tiazol como inhibidores de proteína cinasa B (PKB)
CN101370799B (zh) 2006-01-18 2012-09-05 霍夫曼-拉罗奇有限公司 作为mdm2抑制剂的顺-4,5-二芳基-2-杂环-咪唑啉
AU2007207706A1 (en) 2006-01-18 2007-07-26 Merck Sharp & Dohme Corp. Cannibinoid receptor modulators
US20080242694A1 (en) 2006-09-18 2008-10-02 D Sidocky Neil R Amino-substituted heterocycles, compositions thereof, and methods of treatment therewith

Also Published As

Publication number Publication date
NO20083572L (no) 2008-10-17
US7514566B2 (en) 2009-04-07
UA91895C2 (en) 2010-09-10
EA200801716A1 (ru) 2009-04-28
CA2636077A1 (en) 2007-07-26
WO2007084391A2 (en) 2007-07-26
US8084479B2 (en) 2011-12-27
US20070173506A1 (en) 2007-07-26
ZA200806386B (en) 2009-11-25
CR10211A (es) 2008-10-03
BRPI0706621A2 (pt) 2011-04-05
IL192751A0 (en) 2009-02-11
CN101421265A (zh) 2009-04-29
ES2389062T3 (es) 2012-10-22
PE20071114A1 (es) 2008-01-10
AU2007207743A1 (en) 2007-07-26
MY149143A (en) 2013-07-15
US20090270445A1 (en) 2009-10-29
AU2007207743B2 (en) 2010-07-08
EP1981884B1 (en) 2012-06-13
AR059064A1 (es) 2008-03-12
JP2009525960A (ja) 2009-07-16
KR20080091369A (ko) 2008-10-10
UY30098A1 (es) 2007-10-31
WO2007084391A3 (en) 2008-03-20
TW200738657A (en) 2007-10-16
EP1981884A2 (en) 2008-10-22
CA2636077C (en) 2012-01-03

Similar Documents

Publication Publication Date Title
JP5199885B2 (ja) プロテインキナーゼｂ（ｐｋｂ）阻害剤としてのチアゾール化合物
US7919504B2 (en) Thiadiazole modulators of PKB
US7897619B2 (en) Heterocyclic modulators of PKB
US20110263647A1 (en) Fluoroisoquinoline substituted thiazole compounds and methods of use
ES2538581T3 (es) Compuestos de pirimidina que inhiben la quinasa de linfoma anaplásico
US9505749B2 (en) Quinazolinone compounds and derivatives thereof
WO2013134079A1 (en) Oxazolidinone compounds and derivatives thereof
CA2807093A1 (en) Benzimidazole and azabenzimidazole compounds that inhibit anaplastic lymphoma kinase
WO2004060890A1 (en) 2-oxopyridin-3-yl thia (di) azole derivates for use in the treatment of cell proliferation and apoptosis related diseases
MXPA04011579A (es) Derivados de 2-oxo-2,3,4-trihidroquinazolinilo para el tratamiento de trastornos relacionados con la proliferacion celular.
AU2013205512B2 (en) Benzimidazole and azabenzimidazole compounds that inhibit anaplastic lymphoma kinase

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091125

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20091125

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120710

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20120710

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20121004

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20121012

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130109

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20130205

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20130208

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20160215

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees